Cavazos-Rehg, Patricia A.
Krauss, Melissa J.
Sowles, Shaina J.
Murphy, Gabrielle M.
Bierut, Laura J.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR000448)
National Institute on Drug Abuse (R01DA032843, R01DA039455)
Article History
First Online: 5 July 2017
Compliance with Ethical Standards
:
: This study was funded by the National Institutes of Health [R01DA032843, R01DA039455] and the Washington University Institute of Clinical and Translational Sciences grant [UL1 TR000448] from the National Center for Advancing Translational Sciences (NCATS).
: Dr. Bierut is listed as an inventor on Issued US Patent 8, 080, 371, “Markers for Addiction,” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. All other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study 1. Study 2 was reviewed by the Washington University Human Research Protection Office and granted a non-human determination. Therefore, consent was not needed for this study.